Navigation Links
Kuvan Receives Priority Review Status From Health Canada
Date:6/10/2009

s received seven years of orphan exclusivity in the United States and ten years of market exclusivity in the E.U.

About PKU

PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. To learn more about PKU, please visit www.PKU.com. Information on this website is not incorporated by reference into this press release.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
2. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Kuvan Receives Marketing Approval in the European Union
5. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
10. IsoTis Receives FDA Clearance for Accell Family of Products
11. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... (PRWEB) May 26, 2015 The ... with the Max Planck Society establishing the ... Photonics. The center will link two of the world's ... will be only the third Max Planck Centre in ... international society for optics and photonics, was with ...
(Date:5/26/2015)... HILDEN, Germany , May 26, ... QGEN ; Frankfurt Prime Standard: QIA) today ... Insight ® (QCI™) bioinformatics content and software ... report on genomic variants identified in next-generation sequencing ... bioinformatics platform are in oncology, for somatic and ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Global ... have announced plans for the company’s first cellular and ... followed by a full day, hands-on stem cell training ... J. Victor Garcia Gimenez, M.D., President of Therapeutic Confrontations ... medical community’s increasing interest in regenerative medicine and recent ...
(Date:5/26/2015)... San Diego, CA (PRWEB) May 26, 2015 ... Biopharma, announced the beginning of a long-term relationship ... works on behalf of its members to provide ... “I am extremely pleased to count VGP as ... to more arthritic dog patients nationwide. Concentrating and ...
Breaking Biology Technology:Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 2VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 3
... BOSTON, March 17 Alimera Sciences,and pSivida Ltd ... today announced that,they have amended their license and ... III investigative treatment for,diabetic macular edema (DME), and ... the future profits of Medidur FA from 50 ...
... Contract from Anhui ... Huayuan Pharmaceutical Co., Ltd., ... (OTC Bulletin Board: TYNP), a manufacturer and,supplier of modernized ... that the Company has been granted SFDA,approval and is ...
... March 17 VION,PHARMACEUTICALS, INC. (Nasdaq: VIOND ) ... of 2007., The Company reported a net loss ... ended December 31, 2007, compared with a net loss ... common shares,outstanding for the years ended December 31, 2007 ...
Cached Biology Technology:Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 2Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 3Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 4Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets 2Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets 3Vion Reports 2007 Fourth Quarter and Year-End Results 2Vion Reports 2007 Fourth Quarter and Year-End Results 3Vion Reports 2007 Fourth Quarter and Year-End Results 4
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... 6, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND ... NXT-ID introduces a new revolutionary method and ... the use of miniature antenna modules for multiple ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... at Columbia University's Mailman School of Public Health, the ... Primate Research Center have discovered a key mechanism by ... The identification of an amino acid sequence in Filoviruses ... is described in the December 2006 issue of The ...
... a fish is fit and well? This is a question ... scientists may have come up with the answer - using ... from three UK universities are developing a DNA chip to ... could both save the salmon industry thousands and also help ...
... San Diego (UCSD) School of Medicine have discovered how ... in inflammation and in the body's immune defense against ... These findings could potentially lead to new treatments for ... The research, reported in the December 15, 2006 issue ...
Cached Biology News:Researchers discover key mechanism by which lethal viruses Ebola and Marburg cause disease 2Special chip provides better picture of salmon health 2Special chip provides better picture of salmon health 3UCSD researchers discover internal compass of immune cell 2
... The Vibratome Company has joined forces ... introduce the Vibratome 800 Tissue Chopper. This ... prepare sections of tissue for metabolic experiments ... and irregular specimens available at biopsy or ...
... Custom Peptide Services offer a full range ... research needs. Services include: Peptide synthesis, ... Peptide synthesis, purified product (70-95% pure) ... amidation, biotinylation, fluorescein, myristylation, phosphorylation, and rhodamine) ...
... Open Frame DNAscope is an integrated confocal ... and readily integrated into your specific application. ... we can tailor the system to your ... optical scanning design has been modularized and ...
...
Biology Products: